11β-Prostaglandin F2α MaxSpec Standard | CAS:38432-87-0

• 価格
• 製品情報
• 製品詳細
• 文献

価格

目次に戻る

製品情報

11β-Prostaglandin F_2α (11β-PGF_2α) is the primary plasma metabolite of PGD₂ (Item Nos. 12010 | 10007202) in vivo. Normal human urinary excretion of 11β-PGF_2α is about 54 ng/mmol creatinine, which is increased nearly 3-fold upon allergen-induced bronchoconstriction in asthmatics. It is equipotent to PGF_2α (Item Nos. 16010 | 10007221) in inducing human bronchial smooth muscle contractions and inhibition of adipose differentiation. 11β-PGF_2α inhibits ADP or thrombin-induced human platelet aggregation at concentrations of 0.14-2.8 µM.

11β-PGF_2α MaxSpec^® standard is a quantitative grade standard of 11β-PGF_2α (Item No. 16520) that has been prepared specifically for mass spectrometry or any application where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This 11β-PGF_2α MaxSpec^® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.

目次に戻る

製品詳細

name	11β-Prostaglandin F2α MaxSpec Standard
Formal Name	9α,11β,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid
CAS Number	38432-87-0
Synonyms	11β-PGF2α 11-epi PGF2α
Molecular Formula	C20H34O5
Formula Weight	354.5
Purity	≥95%
Formulation	A solution in ethanol
SMILES	O[C@@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@@H](C/C=C\CCCC(O)=O)[C@@H](O)C1
InChI Code	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19-/m0/s1
InChI Key	PXGPLTODNUVGFL-ZWAKLXPCSA-N
Storage	-20°C
Shipping	Room temperature in continental US; may vary elsewhere
Stability	≥ 1 year

目次に戻る

文献

1. Liston, T.E., and Roberts, L.J., II. Transformation of prostaglandin D2 to 9α,11β-(15S)-trihydroxy-prosta-(5Z,13E)-dien-1-oic acid (9α,11β-prostaglandin F2): A unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc. Natl. Acad. Sci. U.S.A. 82(18), 6030-6034 (1985).

2. O'Sullivan, S., Dahlén, B., Dahlén, S.E., et al. Increased urinary excretion of the prostaglandin D2 metabolite 9α,11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98(2), 421-432 (1996).

3. Coleman, R.A., and Sheldrick, R.L.G. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol. 96(3), 688-692 (1989).

4. Lepak, N.M., and Serrero, G. Inhibition of adipose differentiation by 9α, 11β-prostaglandins F2α. Prostaglandins 46(6), 511-517 (1993).

5. Pugliese, G., Spokas, E.G., Marcinkiewicz, E., et al. Hepatic transformation of prostaglandin D2 to a new prostanoid, 9α,11β-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels. J. Biol. Chem. 260(27), 14621-14625 (1985).

目次に戻る